Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

May 8, 2023 08:09 AM EDT

Recursion acquires two AI-based drug discovery companies in $87.5M deal

Katherine Lewin

News Reporter

AI drug developer Recursion Pharmaceuticals has brought two more AI-focused companies with their own discovery platforms under its wing in an acquisition worth $87.5 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Recursion acquires two AI-based drug discovery companies in $87.5M deal

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Re­cur­sion ac­quires two AI-based drug dis­cov­ery com­pa­nies in $87.5M deal

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Recursion acquires two AI-based drug discovery companies in $87.5M deal